Are you familiar with the role of Janus kinase (JAK) inhibitors for atopic dermatitis (AD)? With over half of patients with AD reporting insufficient disease control, therapeutic management is challenging. In this activity, a dermatology expert explores the rationale behind JAK inhibition for the treatment of AD, clinical trial data on JAK inhibitors for AD, and considering JAK inhibitors when determining patient-specific management of this complex disease.

Click the link below to access the course:
https://www.rapidcme.com/activity.aspx?actID=94